Patterns of calcitonin gene-related peptide monoclonal antibody use in people with migraine: Results of the OVERCOME (US) study

• Published in: Cephalalgia Vol. 45; no. 6; p. 3331024251341243
• Main Authors: Ashina, Sait, Kim, Gilwan, Muenzel, E. Jolanda, Buse, Dawn C., Zagar, Anthony J., Zakharyan, Armen, Shapiro, Robert E., Nicholson, Robert A., Pearlman, Eric M., Lipton, Richard B.
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.06.2025
• Subjects: Adult; Antibodies, Monoclonal - therapeutic use; Calcitonin Gene-Related Peptide - antagonists & inhibitors; Calcitonin Gene-Related Peptide - immunology; Calcitonin Gene-Related Peptide Receptor Antagonists - therapeutic use; Cohort Studies; Female; Humans; Male; Middle Aged; Migraine Disorders - drug therapy; Migraine Disorders - epidemiology; Migraine Disorders - prevention & control; United States; United States; migraine; monoclonal antibody; CGRP; OVERCOME

Background Understanding characteristics and reasons associated with using calcitonin gene-related peptide monoclonal antibodies (CGRP mAb) for migraine prevention may help clinicians individualize treatment plans and achieve better patient outcomes. Methods We analyzed 2019–2020 cohort data of OVER...